Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roderick Haithcock

Internal Medicine Richmond, VA Medical Doctor

NPI 1801884580 CMS profile 81220

505 W. Leigh Street, Suite 303, Richmond, VA 23220

Open in the dashboard

General payments

$3,586

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roderick Haithcock of Richmond, VA is reported in the CMS Open Payments database as having received $3,586 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $67 4
2024 General $212 9
2023 General $786 48
2022 General $976 53
2021 General $764 42
2020 General $145 9
2019 General $636 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roderick Haithcock
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Roderick Haithcock were reported at $67. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Roderick Haithcock Internal Medicine median Middle half National median
2019 $636 $159 $48–$570 $163
2020 $145 $119 $33–$402 $114
2021 $764 $135 $37–$521 $132
2022 $976 $141 $42–$496 $149
2023 $786 $149 $45–$519 $160
2024 $212 $154 $47–$537 $164
2025 $67 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $345 23 payments
  2. Abbott Laboratories $313 15 payments
  3. AbbVie, Inc. $270 20 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $246 13 payments
  5. Sanofi-Aventis U.S. LLC $219 12 payments
  6. Novartis Pharmaceuticals Corporation $191 13 payments
  7. Amgen Inc. $181 11 payments
  8. Lilly USA, LLC $162 10 payments
  9. Astellas Pharma US Inc $160 5 payments
  10. AstraZeneca Pharmaceuticals LP $129 9 payments
  11. Other $1,369 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,487 206 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. Kerendia $246 13 payments
  2. ENTRESTO $159 11 payments
  3. VRAYLAR $152 12 payments
  4. Ozempic $150 9 payments
  5. FreeStyle Libre 2 $142 6 payments
  6. RYBELSUS $123 7 payments
  7. FreeStyle Libre 3 $115 6 payments
  8. TRULICITY $104 7 payments
  9. GEMTESA $86 5 payments
  10. Repatha $79 5 payments
  11. Other $2,480 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 181 drugs

Part D claims

15,484

Median for Internal Medicine: 777

Drug cost

$1,484,519

Median for Internal Medicine: $73,373

Branded share of claims

27.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 251 $258,166
Jardiance Empagliflozin Brand 198 $202,603
Mounjaro Tirzepatide Brand 162 $182,915
Trulicity Dulaglutide Brand 92 $101,758
Eliquis Apixaban Brand 147 $100,168
Ozempic Semaglutide Brand 61 $70,501
Januvia Sitagliptin Phosphate Brand 58 $68,051
Entresto Sacubitril/Valsartan Brand 50 $41,814
Xarelto Rivaroxaban Brand 35 $40,488
Myrbetriq Mirabegron Brand 36 $25,917

The 10 drugs with the highest cost, of 181 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$104,846

Of which drugs: $2,329

Medicare patients

304

Average age 74

Services billed

1,638

175 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Arthritis 43%
Chronic kidney disease 40%
Heart failure 20%
Ischemic heart disease 19%
Cancer 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 28 28 $2,291

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record